Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor

doi:10.5246/jcps.2016.02.016

Abstract

Abstract:

In the present study, we aimed to evaluate the efficiency and cost of pirarubicin (THP) and epirubicin (EPI) as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor (TUR-BT). Standardized evaluation was performed by analyzing research papers. Moreover, expert opinions, studies and cost data were combined to evaluate cost of THP and EPI. With systematic review and expert opinions, we confirmed that THP and EPI were not statistically different when they were used as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after TUR-BT. Moreover, the cost evaluation of THP and EPI needs to be separately discussed according to original/generic drug. The original drug THP had more cost advantages than EPI, while generic EPI had more cost advantages than THP.

Key words: Pirarubicin, Epirubicin, Cost, Superficial bladder cancer

CLC Number:

R951

Supporting:

Cite this article

Lili Ma, Qimin Lin, Sheng Han, Fei Yu, Luwen Shi. Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(2): 145-149.

share this article

0
/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://jcps.bjmu.edu.cn/EN/10.5246/jcps.2016.02.016

http://jcps.bjmu.edu.cn/EN/Y2016/V25/I2/145

References

[1] Parkin, D.M.; Bray, F.; Ferlay, J. CA Cancer J. Clin. 2005, 55, 74-108.

[2] Wu, J.P. Wu Jieping Urology [M], Jinan: Shandong Science and Technology Press. 2004, 919-942.

[3] Sobin, L.H.; Wittekind, C. TNM Classification of Malignant Tumors. 2002, 199-202.

[4] Lamm, D.L. Urol. Clin. North Am. 1992, 19, 499-508.

[5] Tolley, D.A.; Parmar, M.K.; Grigor, K.M.; Lallemand, G.; Benyon, L.L.; Fellows, J.; Freedman, L.S.; Grigor, K.M.; Hall, R.R.; Hargreave, T.B.; Munson, K.; Newling, D.W.; Richards, B.; Robinson, M.R.; Rose, M.B.; Smith, P.H.; Williams, J.L.; Whelan, P. J. Urol. 1996, 155, 1233-1238.

[6] Sylvester, R.J.; van der Meijden, A.P.M.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Eur. Urol. 2006, 49, 466-477.

[7] Onrust, S.V.; Wiseman, L.R.; Goa, K.L. Drugs Aging. 1999, 15, 307-333.

[8] Ali-el-Dein, B.; El-Baz, M.; Aly, A.N.; Ashamallah, A. J. Urol. 1997. 158, 68-73, 73-74.

[9] Imamoglu, M.A.; Bakirtas, H.; Yigitbasi, O.; Sertçelik, A.N. Arch. Esp. Urol. 2001, 54, 1147-1153.

[10] Shinohara, N.; Nonomura, K.; Tanaka, M.; Nagamori, S.; Takakura, F.; Seki, T.; Koyanagi, T.; Togashi, M.; Maru, A. Cancer Chemother. Pharmacol. , 35, S41-S45.1994

[11] Tang, H.; Tang, Y.Z.; Chen, X.D.; Ding, M.T.; Zhang, W.D.; Xiao, J. J. Mod. Urol. 2008, 1, 38-40.

[12] Li, W.C.; Liu, J.; Xu, L.W.; Shen, M.S. China Prac. Med. 2009, 31, 32-33.

[13] Jiang, D.F.; Zeng, M.H.; Wu, Y.; Jiang, H.; Wu, A.B.; Yu, X.M. J. Qiqihar Med. Coll. , 21, 3407-34082010.

[14] Tao, H.W.; Han, Z.H. Strait Pharm. J. 2012, 4, 211-212.

[15] Chen, X.J.; Xia, Z.H.; Chen, M.Z.; Huo, J.G. Chin. Gen. Prac. 2012, 19, 2188-2190.

Related Articles 15

[1]	Wentao Zhu, Wanglong Hong, Miaomiao Zheng, Guoqiang Ma, Aizong Shen. Combination of pembrolizumab and chemotherapy as first-line treatment in advanced triple-negative breast cancer: a cost-effectiveness analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 587-597.
[2]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[3]	Jun Ma, Liangyu Ni, Qiyun Zhu, Zhao Yang, Bin Jiang. Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease (iMCD) in China [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 842-851.
[4]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Study of the economic burden and influencing factors on stroke patients in Central China in the post-epidemic era [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(7): 545-555.
[5]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[6]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[7]	Yingzi Bu, Limin Mu, Lei Liu, Wanliang Lu. Construction of folate-conjugated epirubicin liposomes for enhancing the cellular uptake and the co-localization with nuclei of invasive breast cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 229-240.
[8]	Fangbing Lv, Kewei Yu, Wenwen Gao, Shuwen Yu. Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(6): 447-454.
[9]	Limin Mu, Jiashuan Wu, Hongjun Xie, Lei Liu, Fan Zeng, Yan Yan, Yao Zhao, Yingjie Hu, Yingzi Bu, Wanliang Lu. The use of a new functional glucose conjugate material, TPGS1000-Glu, in treatment of brain glioma by incorporating into epirubicin liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(4): 266-274.
[10]	Min Zhang, Guochun Bao, Kun Zhao, Xue Li. Implications of clinical pathway reform on pharmaceutical costs at a hospital in Qingdao city [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(2): 154-158.
[11]	Lei Liu, Ruijun Ju, Hongjun Xie, Fan Zeng, Chengjiang Zhang, Weiyu Zhao, Wanliang Lu. Efficacy and mechanism of a compound epirubicin plus quinine injection for the treatment of drug-resistant breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(9): 563-571.
[12]	Sheng Han, Kuan Wang, Run Pu, Luwen Shi^*. Economic evaluation of soft silicon foam dressings versus sterile gauze for the treatment of pressure ulcers in China [J]. , 2013, 22(5): 456-460.
[13]	Xin Zong, Li-Hua Sun^*. A review of the methods for determining cost-effectiveness threshold in health care [J]. , 2011, 20(6): 542-548.
[14]	Ying Men, Xiao-Xing Wang, Rui-Jun Ju, Wei Tian, Xue Ying, Hong-Juan Yao, Yan Zhang, Ruo-Jing Li, Wan-Liang Lu^* . Development of an HPLC-UV method for the simultaneous determination of epirubicin, amlodipine and dequalinium in anti-resistant liposomes [J]. , 2010, 19(4): 300-306.
[15]	Dong Mei, Feng Fengyi^*, Fu Qiang, Zhu Zhu. Study on Pharmacokinetics and Pharmacodynamics of High Dose Epirubicin in Cancer Patients [J]. , 2000, 9(2): 92-95.

Metrics

Viewed

Full text

Abstract

Comments

Abstract
References
Related Articles
Recommended Articles
Metrics
Comments

TOP